149.86
Illumina Inc stock is traded at $149.86, with a volume of 1.85M.
It is down -1.47% in the last 24 hours and up +11.05% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$152.09
Open:
$152.42
24h Volume:
1.85M
Relative Volume:
1.02
Market Cap:
$22.90B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
33.57
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-1.72%
1M Performance:
+11.05%
6M Performance:
+36.39%
1Y Performance:
+12.16%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
149.86 | 23.24B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
608.02 | 234.41B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
224.54 | 166.52B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
687.74 | 55.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
239.76 | 41.05B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.87 | 38.54B | 6.95B | 1.30B | 1.15B | 4.5696 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products - TradingView
Retirement Systems of Alabama Sells 7,647 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Analyst Verdict: Illumina In The Eyes Of 15 Experts - Benzinga
Microarrays Market Size to Accumulate Around USD 10.72 Billion by 2033, Driven by Expanding Genomics Research and Advanced Diagnostic Adoption – SNS Insider - GlobeNewswire Inc.
Illumina price driven lower by pivotal resistanceForecast today26-01-2026 - Economies.com
Canaccord Genuity raises Illumina stock price target to $150 on solid results - Investing.com
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Wealth Enhancement Advisory Services LLC Buys 9,997 Shares of Illumina, Inc. $ILMN - MarketBeat
iA Global Asset Management Inc. Purchases New Position in Illumina, Inc. $ILMN - MarketBeat
9,062 Shares in Illumina, Inc. $ILMN Purchased by Rakuten Investment Management Inc. - MarketBeat
Illumina Inc. (ILMN) shares see target boost as analysts see potential 2026 upside - MSN
Is It Time To Reconsider Illumina (ILMN) After Mixed Multi Year Share Performance? - Yahoo Finance
Customer Engagement Center - Illumina
Baillie Gifford & Co. Lowers Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine
Whole Genome and Exome Sequencing: Global Market Review 2021-2025 and Growth Outlook 2026-2031 Featuring Illumina, Thermo Fisher Scientific, BGI Genomics and Other Leading Players - Yahoo Finance
Illumina, Inc. $ILMN Shares Sold by Teacher Retirement System of Texas - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN - MarketBeat
$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 - GlobeNewswire
$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies and Other Leading Players - Yahoo Finance UK
United States Agrigenomics Market | CAGR 8% | North America Leads - openPR.com
Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing
Illumina stock hits 52-week high at 151.35 USD By Investing.com - Investing.com Australia
Dubai Health embraces genomics to advance care and research - Illumina
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years - Sahm
Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest - Yahoo Finance
The Truth About Illumina Inc.: Is This Genomics Giant Still Worth Your Money? - AD HOC NEWS
Illumina (NASDAQ:ILMN) Sets New 52-Week HighHere's What Happened - MarketBeat
Illumina and Powell Gilbert in love with Lisbon - JUVE Patent
Illumina stock hits 52-week high at 151.35 USD - Investing.com
Illumina secures CMS reimbursement for cancer genomic test at $2,989 By Investing.com - Investing.com South Africa
11,407 Shares in Illumina, Inc. $ILMN Acquired by Inscription Capital LLC - MarketBeat
North America Bioinformatics Market Size, Share, Trends, - openPR.com
Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55 - Intellectia AI
Illumina Gets Medicare Boost for Cancer Test, Shares Climb - Benzinga
Evaluating next‑generation cloud compute for large‑scale genomic processing - Amazon Web Services (AWS)
Illumina secures CMS reimbursement for TruSight™ Oncology Compre - GuruFocus
Illumina secures CMS reimbursement for cancer genomic test at $2,989 - Investing.com
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq
Press Release - Illumina
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology - PR Newswire
Stifel raises Illumina stock price target to $155 on growth outlook - Investing.com
GRAIL Inc.Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha
Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Finviz
The Technical Signals Behind (ILMN) That Institutions Follow - Stock Traders Daily
Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan
Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance
2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026] - 2 Minute Medicine
Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? - 富途资讯
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):